Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin Combined With CSII in Newly Diagnosed T2DM
NCT04120623Phase 4Unknown
- Sponsor
- Nanjing First Hospital
- Start
- Oct 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
01
Overview
Phase 4, randomised trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Nanjing First Hospital. Primary endpoint: Glucose profile by continuous glucose monitoring system at 5 weeks. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04120623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04120623.